Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
| ▸ | GABRE | P78334 | 1/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.30 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.30 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.30 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15415249 | 1.00 | PSIP1 (0.32) | PSIP1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL15416377 | 0.89 | PSIP1 (0.41) | PSIP1 | |
| SCHEMBL15429055 | 0.82 | SMN1; SMN2 (0.32) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15415086 | 0.82 | SMN1; SMN2 (0.32) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14971973 | 0.81 | CYP3A4 (0.45) | PSIP1 | |
| SCHEMBL14576782 | 0.78 | P2RX7 (0.35) | — | |
| SCHEMBL14576783 | 0.78 | P2RX7 (0.35) | — | |
| SCHEMBL10157239 | 0.78 | MEN1 (0.45) | PSIP1 | |
| SCHEMBL14576726 | 0.78 | P2RX7 (0.33) | — | |
| SCHEMBL14577272 | 0.78 | P2RX7 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877468-B1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LTD (GB) | 2017-08-23 | — | — | EP | disclosed |
| US-9163023-B2 | Compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-10-20 | — | — | US | disclosed |
| US-20150191469-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-07-09 | — | — | US | disclosed |
| EP-2877468-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014009794-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191469-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | CCR5, CD4, HAVCR2 | PSIP1 1098/4885GABRP 1686/4885GABRD 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.